AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

U.S. stock futures are edging higher after the Federal Reserve's jumbo-sized interest-rate cut last week. Here's what investors need to know today. Intel (INTC) shares are jumping 4% in premarket ...

UK shares slipped on Monday after logging their worst day since August in the previous session, while investors awaited flash ...